Du Z, Pandey A, Moghadas SM, Bai Y, Wang L, Matrajt L, Singer BH, Galvani AP, Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults, Nature Medicine 2025, 1-6.
Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, Galvani AP. Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States. Clinical Infectious Diseases. 2024, 78(5): 1328-1335.
Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM, Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: A simulation study, The Lancet Regional Health - Americas 2023, 28: 100629.
Sah P, Vilches TN, Moghadas SM, Gondi S, Schneider EC, Singer J, Chokshi DA, Galvani AP, Return on investment of the COVID-19 vaccination campaign in New York City, JAMA Network Open 2022, 5(11): e2243127.
Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, Galvani AP, The implications of silent transmission for the control of COVID-19 outbreaks, Proceedings of the National Academy of Sciences USA 2020, 117(30): 17513–17515.
For citation of our published studies, visit Google Scholar
Chen L, Mukerjee G, Dorfman R, Moghadas SM, Disease risk assessment using a Voronoi-based network analysis of genes and variants scores, Frontiers in Genetics 2017, 8: 29.
Moghadas SM, Shoukat A, Espindola A, Pereira RS, Abdirizak F,Laskowski M, Viboud C, Chowell G, Asymptomatic transmission and the dynamics of Zika infection, Scientific Reports 2017, 7: 5829.
Maghdoori S, Moghadas SM, Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings, BMC Infectious Diseases 2017, 17: 384.
Champredon D, Moghadas SM, Quantifying the contribution of asymptomatic infection to the cumulative incidence, Epidemiology and Infection 2017, 145: 1256–1258.
Moghadas SM, Mathematical modelling of tuberculosis, Mathematical Population Studies 2017, 24: 1-2.
Knipl D, Röst G, Moghadas SM, Population dynamics of epidemic and endemic states of drug-resistance emergence in infectious diseases, PeerJ 2017, 5: e2817.
Brauer F, Xiao Y, Moghadas SM, Drug-resistance in an age-of-infection model, Mathematical Population Studies 2017, 24: 64–78.
Espindola A, Varughese M, Laskowski M, A. Shoukat, Heffernan J, Moghadas SM, Strategies for halting the rise of MDR-TB epidemic: assessing the effect of early case detection and isolation, International Health 2017, 9: 80–90.
Shoukat A, Espindola A, Röst G, Moghadas SM, How the interval between primary and booster vaccination affects long-term disease dynamics, Mathematical Biology and Biological Physics 2017, 60–71.
Charania N, Moghadas SM, Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b, BMC Public Health 2017, 17: 705.